Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Trends Cancer. 2022 Feb 18;8(5):397–403. doi: 10.1016/j.trecan.2022.01.004

Key Figure. Schematic of emerging signaling mediators in the cancer anorexia-cachexia syndrome.

Key Figure.

The signaling mediators activin A, GDF15, and lipocalin-2 and their roles in the cancer anorexia-cachexia syndrome are displayed. Activin and GDF15 are believed to be synthesized and secreted largely from tumors and circulate to peripheral organs to regulate feeding (GDF15), and adipose and skeletal muscle atrophy (activin A). Lipocalin-2 is generated from bone marrow-derived neutrophils and circulates to the brain to regulate anorexia. The human outline is meant to portray the translational potential of targeting these signaling mediators as a therapy for cancer cachexia.